Novo Nordisk Wegovy

Wegovy is a brand of semaglutide developed by the Danish pharmaceutical giant Novo Nordisk. Originally formulated as a treatment for chronic weight management, it has become one of the most recognizable names in modern clinical healthcare. The medication is manufactured across a global network of specialized facilities, with key production sites located in Denmark, the United States, and France to meet international demand.

The brand's history is deeply rooted in Denmark, where Novo Nordisk was established over a century ago. Today, the company remains the ultimate owner and operates as a world leader in diabetes and obesity care. The ownership structure is stabilized by the Novo Nordisk Foundation, which ensures the company maintains a long-term focus on medical innovation and research. Wegovy represents a significant milestone in the company's expansion from insulin-based treatments into the broader metabolic health sector.